2027 NCODA Global Oncology & Haematology Congress
March 10, 2027 | 9:00 AM EST
A5 / P5
NCODA Oncology and Hematology Meeting Abstracts | Volume 2 | Supplement 2
Publication Date: October 28, 2026
Assessing value-based care metrics and clinical outcomes by hormone receptor status among patients with human epidermal growth factor receptor 2-positive breast cancer
Organization / Company:
1Cancer Specialists of North Florida, LLC, Jacksonville, FL, USA, 2University of Florida College of Pharmacy, Department of Pharmacy Education and Practice, Jacksonville, FL, USA
NCODA Oncol Hematol Meet Abstr. 2026;2(suppl 2):abstr 5.
Share
Background:
The financial burden of cancer care has continued to rise, with national cancer expenditures projected to reach $246 billion by 2030. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for approximately 25% of all breast cancers, with breast cancer being the most diagnosed malignancy and the second leading cause of cancer-related mortality among women. Recurrent, unresectable, or metastatic HER2-positive breast cancer is associated with substantial healthcare utilization and significantly higher costs compared with earlier-stage disease. Despite this growing economic impact, data evaluating healthcare utilization within value-based care (VBC) frameworks remain limited, particularly with respect to timealigned treatment cohort comparisons and clinically relevant subpopulations. For privately owned institutions participating in VBC programs, preserving therapeutic efficacy remains central to every treatment decision and necessitates individualized patient assessment prior to regimen selection. However, given that available regimens may differ in toxicity profiles, identifying preferred treatment pathways that minimize risk exposure and reduce overall patient and practice expenditure is of increasing importance and ultimately advances the core objective of VBC programs.
Objectives:
- Identify trends in healthcare utilization among patients who received trastuzumab deruxtecan-nxki compared to other HER2-directed therapies.
- Compare clinical endpoints among various timealigned treatment cohorts.
Study Design:
This retrospective chart review describes realworld treatment patterns among patients with HER2-positive breast cancer who received treatment for unresectable or metastatic disease. Specifically, this study seeks to characterize the rate of downstream healthcare utilization records amongst patients who received trastuzumab deruxtecan-nxki compared to a time-aligned treatment cohort receiving alternative standard-of-care therapies.
Methods:
Eligible patients include adults diagnosed with unresectable or metastatic (Stage IV) HER2-positive (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]-) breast cancer who received any line of HER2-positive-directed therapy for their current disease status between May 1, 2021, and May 1, 2026, within selected practice location(s). Analyses will be stratified by patient demographics, HER2-expression testing methods (IHC and/or ISH), hormone receptor status, treatment, and outcome measures. Clinical outcomes of interest include real-world progression-free survival, adverse event details, and location of new metastasis, if applicable. Key VBC metrics include rates of inpatient admissions, emergency department visits, unscheduled outpatient visits, and time to first downstream healthcare utilization measured in days, as identified in the patient chart or health information exchange data.
Current Status:
Results and corresponding conclusions are currently in progress and will be presented upon completion of the analysis.
Expected Impact:
The expected impact of this study is to characterize real-world prescribing patterns and their associated healthcare utilization among patients with HER2-positive unresectable or metastatic breast cancer. Together, these results may inform clinical decision-makers at the practice and VBC program level regarding preferred treatment algorithms for patients enrolled in the program.
Funding: Not applicable.
Send your feedback
Please do not include any personal information or details.
"*" indicates required fields
Was this page
helpful?
Send your feedback
Please do not include any personal information or details.
"*" indicates required fields